Enterprise Science

Enterprise Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel disease-modifying therapies for respiratory diseases, with a primary focus on cystic fibrosis (CF). The company's approach centers on enhancing mucociliary clearance by targeting ion channels to increase hydration and reduce mucus viscosity in the airways. Their lead program, ETD001, is a long-acting ENaC inhibitor designed to provide benefit to all CF patients regardless of their underlying genetic mutation. By addressing the fundamental problem of mucus congestion, Enterprise Therapeutics aims to provide transformative treatments for patients with severe respiratory conditions including CF, asthma, and COPD.